Properties |
Information |
PhytoCAT-ID |
PhytoCAT-1991 |
Phytochemical name or plant extracts |
Xanthone V |
PMID |
21886765 |
Literature evidence |
In the present work, we carried out a preliminary screening of six natural compounds, xanthone V(1) (1); 2-acetylfuro-1,4-naphthoquinone (2); physcion (3); bisvismiaquinone (4); vismiaquinone (5); 1,8-dihydroxy-3-geranyloxy-6-methylQuinone (6) against MiaPaCa-2 pancreatic and CCRF-CEM leukemia cells and their multidrug-resistant subline, CEM/ADR5000. |
IUPAC name |
methanol;5,9,10-trihydroxy-2,2-dimethyl-12-(3-methylbut-2-enyl)pyrano[3,2-b]xanthen-6-one |
Phytochemicals’ class or type of plant extracts |
Xanthone |
Source of phytochemicals or plant Extracts |
Vismia laurentii |
|
Geographical availability |
Cameroon, Central African Repu, Congo, Zaïre |
Plant parts |
NA |
Other cancers |
Breast cancer |
Target gene or protein |
Caspase 3, Caspase 7 |
Gene or Protein evidence |
Caspase 3/7 was activated by xanthone V(1) |
Target pathways |
NA |
IC50 |
0.56±0.06 µg/ml against MCF-7 |
Potency |
The overall results of the present study provided evidence for the cytotoxicity of compounds xanthone V(1) and 2-acetylfuro-1,4-naphthoquinone, and bring supportive data for future investigations that will lead to their use in cancer therapy. |
Cell line/ mice model |
CCRF-CEM, CEM/ADR5000, PF-382, HL-60, MiaPaCa-2, Capan-1, MCF-7, SW-680, 786-0, U87MG, A549, Colo-38, HeLa, Caski |
Additional information |
The most sensitive cancer cell lines to xanthone V1 and 2-acetylfuro-1,4-naphthoquinone were Colo-38 (melanoma), HeLa and Caski (cervix cancer) with IC50 values being closer or lower those obtained with doxorubicin.
In addition, MCF-7 (breast cancer) and PF-382 (leukemia) also showed high sensitivity to xanthone V1 and 2-acetylfuro-1,4-naphthoquinone respectively. |
PubChem ID |
139068057 |
Additional PMIDs |
NA |
Additional sources of information |
https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:77185673-1 |
Safety |
NA |